Name: Kynurenic acid
Brand: Selleck Chemicals
SKU: S4719
Rating: 5 (4 reviews)

Saltar a

Control de calidad (Quality Control)

Lote: Pureza: 99.94%

99.94

Dianas relacionadas	Adrenergic Receptor AChR 5-HT Receptor COX Calcium Channel Histamine Receptor Dopamine Receptor GABA Receptor TRP Channel Cholinesterase (ChE)
Otros NMDAR Inhibidores	(+)-Dizocilpine (MK 801) Maleate NMDA (N-Methyl-D-aspartic acid) (-)-Dizocilpine (MK 801) Maleate Ifenprodil Tartrate Memantine HCl Spermidine trihydrochloride Quinolinic acid Mephenesin Sarcosine D-Aspartic acid

Información química, almacenamiento y estabilidad (Chemical Information, Storage & Stability)

Peso molecular	189.17	Fórmula	C₁₀H₇NO₃	Almacenamiento (Desde la fecha de recepción)	3 años-20°Cpolvo
Nº CAS	492-27-3	Descargar SDF		Almacenamiento de soluciones madre	1 año-80°Cen disolvente 1 mes-20°Cen disolvente
Sinónimos	Quinurenic acid, Kynurenate			Smiles	C1=CC=C2C(=C1)C(=O)C=C(N2)C(=O)O

Solubilidad (Solubility)

In vitro
Lote:

DMSO : 19 mg/mL (100.43 mM)
(El DMSO contaminado con humedad puede reducir la solubilidad. Usar DMSO fresco y anhidro.)

Water : Insoluble

Ethanol : Insoluble

Calculadora de Molaridad

Masa	Concentración	Volumen	Peso molecular
=	×	×

Calculadora de Dilución Calculadora de Peso Molecular

In vivo Lote:
Homogeneous suspension	CMC-NA	≥5mg/ml	Taking the 1 mL working solution as an example, add 5 mg of this product to 1 ml of CMC-Na solution, mix evenly to obtain a homogeneous suspension with a final concentration of 5 mg/ml.
Homogeneous suspension	CMC-NA	≥5mg/ml	Taking the 1 mL working solution as an example, add 5 mg of this product to 1 ml of CMC-Na solution, mix evenly to obtain a homogeneous suspension with a final concentration of 5 mg/ml.
Homogeneous suspension	CMC-NA	≥5mg/ml	Taking the 1 mL working solution as an example, add 5 mg of this product to 1 ml of CMC-Na solution, mix evenly to obtain a homogeneous suspension with a final concentration of 5 mg/ml.
Homogeneous suspension	CMC-NA	≥5mg/ml	Taking the 1 mL working solution as an example, add 5 mg of this product to 1 ml of CMC-Na solution, mix evenly to obtain a homogeneous suspension with a final concentration of 5 mg/ml.
Homogeneous suspension	CMC-NA	≥5mg/ml	Taking the 1 mL working solution as an example, add 5 mg of this product to 1 ml of CMC-Na solution, mix evenly to obtain a homogeneous suspension with a final concentration of 5 mg/ml.
Clear solution	5%DMSO 1 40%PEG300 2 5%Tween80 3 50%ddH2O Validado por los laboratorios Selleck. Si necesita ajustes en esta formulación, contacte con nuestro equipo de ventas para pruebas personalizadas.	0.500mg/ml (2.64mM)	Taking the 1 mL working solution as an example, add 50 μL of 10 mg/ml clarified DMSO stock solution to 400 μL of PEG300, mix evenly to clarify it; add 50 μL of Tween80 to the above system, mix evenly to clarify; then continue to add 500 μL of ddH2O to adjust the volume to 1 mL. The mixed solution should be used immediately for optimal results.
Clear solution	5% DMSO 1 95% Corn oil Validado por los laboratorios Selleck. Si necesita ajustes en esta formulación, contacte con nuestro equipo de ventas para pruebas personalizadas.	0.250mg/ml (1.32mM)	Taking the 1 mL working solution as an example, add 50 μL of 5 mg/ml clear DMSO stock solution to 950 μL of corn oil and mix evenly. The mixed solution should be used immediately for optimal results.

Calculadora de formulación in vivo (Solución clara)

Paso 1: Introduzca la información a continuación (Recomendado: Un animal adicional para tener en cuenta la pérdida durante el experimento)

Dosis: mg/kg Peso promedio de los animales: g Volumen de dosificación por animal:μL Número de animales:

Paso 2: Introduzca la formulación in vivo (Esto es solo la calculadora, no la formulación. Por favor, contáctenos primero si no hay una formulación in vivo en la sección de Solubilidad.)

% DMSO + % + % Tween 80 + % ddH₂O

%DMSO+ %

Resultados del cálculo:

Concentración de trabajo: mg/ml;

Método para preparar el líquido maestro de DMSO: mg fármaco predissuelto en μL DMSO ( Concentración del líquido maestro mg/mL, Por favor, contáctenos primero si la concentración excede la solubilidad del DMSO del lote del fármaco. )

Método para preparar la formulación in vivo: Tomar μL DMSO líquido maestro, luego añadirμL PEG300, mezclar y clarificar, luego añadirμL Tween 80, mezclar y clarificar, luego añadir μL ddH₂O, mezclar y clarificar.

Método para preparar la formulación in vivo: Tomar μL DMSO líquido maestro, luego añadir μL Aceite de maíz, mezclar y clarificar.

Nota: 1. Por favor, asegúrese de que el líquido esté claro antes de añadir el siguiente disolvente.
2. Asegúrese de añadir el (los) disolvente(s) en orden. Debe asegurarse de que la solución obtenida, en la adición anterior, sea una solución clara antes de proceder a añadir el siguiente disolvente. Se pueden utilizar métodos físicos como el vórtice, el ultrasonido o el baño de agua caliente para ayudar a la disolución.

Mecanismo de acción (Mechanism of Action)

Targets/IC₅₀/Ki	α7 nicotinic acetylcholine receptor glutamate receptors NMDAR
In vitro	Kynurenic acid(KYNA) is neuroactive tryptophan metabolites formed along the kynurenine pathway. It is considered a non-competitive antagonist of glutamate receptors of NMDA type. KYNA, at low concentration, inhibits FGF-1 release in all cellular models and displays a major stimulatory effect on the proliferation rate of mouse microglia and human glioblastoma cells, in vitro.
In vivo	Treatment with KYNA (30–100 mg per kg of body weight, intravenously) 4 h before the start of heat stress significantly (P<0.05) and dose-dependently decreases the survival time to new values of 152–356 min compared with normothermic rats. KYNA protects against hypotension but not hyperthermia during heatstroke. KYNA attenuates hypothalamic neuronal degeneration and apoptosis during heatstroke. Also spleen, kidney, liver, and lung apoptosis during heatstroke are decrease. KYNA up-regulates serum IL-10 levels but down-regulates serum TNF-α and ICAM-1 levels. KYNA treatment significantly prevents the occurrence of heat-induced multi-organ damage and inflammation without affecting the induced hyperthermia. Only high doses of KYNA proved to be neuroprotective in neonatal rats by reducing anoxia or hypoxia-ischemia-induced brain edema and in adult rats and gerbils given before ischemia induction. KYNA cannot cross the blood-brain barrier.
Referencias	[1] https://pubmed.ncbi.nlm.nih.gov/25674503/ [2] https://pubmed.ncbi.nlm.nih.gov/16392031/ [3] https://pubmed.ncbi.nlm.nih.gov/21293468/ [4] https://pubmed.ncbi.nlm.nih.gov/6215086/

Información del ensayo clínico (Clinical Trial Information)

(datos de https://clinicaltrials.gov, actualizado el 2024-05-22)

Número NCT	Reclutamiento	Condiciones	Patrocinador/Colaboradores	Fecha de inicio	Fases
NCT06029296	Not yet recruiting	Alcohol Use Disorder	University of Maryland Baltimore	April 2024	Early Phase 1
NCT06314503	Recruiting	Renal Insufficiency Chronic\|Kidney Failure Chronic\|Chronic Kidney Diseases	UMC Utrecht\|European Commission Horizon 2020\|Dutch Kidney Foundation\|Health Holland\|Nanodialysis Ltd\|Università degli studi di Modena e Reggio Emilia (UNIMORE)\|Servicio Madrileno De Salud (SERMAS)\|PPI Healthcare Consulting Ltd	January 22 2024	Not Applicable
NCT05488951	Recruiting	Dementia	Augusta University	July 1 2022	Not Applicable
NCT05969990	Recruiting	Migraine in Children	Qilu Hospital of Shandong University	January 1 2022	--
NCT05280054	Unknown status	Drug Drug Interaction	VistaGen Therapeutics Inc.\|Parexel	December 23 2021	Phase 1

C1=C0/X	C1:	LOG(C1):
C2=C1/X	C2:	LOG(C2):
C3=C2/X	C3:	LOG(C3):
C4=C3/X	C4:	LOG(C4):
C5=C4/X	C5:	LOG(C5):
C6=C5/X	C6:	LOG(C6):
C7=C6/X	C7:	LOG(C7):
C8=C7/X	C8:	LOG(C8):

Kynurenic acid NMDAR antagonist

Estructura química

Peso molecular: 189.17